Abstract
The clinical outcomes and safety of dalbavancin as primary and sequential treatment of gram-positive bacteremia with infective endocarditis were evaluated retrospectively. The clinical success rate was high (92.6%), but in 24 of 27 patients dalbavancin was used only after clearance of bacteria from the bloodstream.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Anti-Bacterial Agents / therapeutic use*
-
Austria
-
Bacteremia / drug therapy
-
Endocarditis, Bacterial / drug therapy*
-
Female
-
Gram-Positive Bacterial Infections / blood
-
Gram-Positive Bacterial Infections / drug therapy*
-
Hospitals, General
-
Humans
-
Male
-
Middle Aged
-
Retrospective Studies
-
Teicoplanin / analogs & derivatives*
-
Teicoplanin / therapeutic use
-
Treatment Outcome
Substances
-
Anti-Bacterial Agents
-
Teicoplanin
-
dalbavancin